Technology

With digital interventions in drug adherence regimes evolving to new levels of sophistication, Pharm Exec looks at the ongoing patient-behavior and privacy issues that still present significant challenges.

The rapid development and take-up of digital technology is forever changing the way pharma engages with patients-but the industry’s ultimate potential in tapping digital health to transform patient care hinges on embracing new shifts in culture and business strategy.

Separating the meaningful from the merely novel, Bill Drummy outlines his Top Ten digital marketing trends for 2017.

With the physician-access climate as daunting as ever for sales reps, four best practices in implementing artificial intelligence-based technology to help achieve engagement wins are explored.

Q&A spotlights the development of one injection device that is helping change the treatment-adherence landscape.

Big data has proven to be a valuable business asset, but using it to gain competitive advantage requires the right combination of strategy, technology and execution, write Mahmood Majeed, Vickye Jain, and Sandeep Varma.

Multi-channel marketing manager Adi Borovick discusses the implications of compliance for marketers in a world where new technologies being created every day.

In the 21st Century Cures Act, Congress excluded from FDA regulation certain clinical decision support, or CDS, software.

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

The digital workplace is defined as a “business strategy to boost employee engagement and agility through a more consumerized work environment”. But what exactly does this mean for life sciences organizations? Michael Woodbridge explains.

It’s no longer sufficient for a pharma to develop better products or even build simple apps. The industry increasingly needs to create sophisticated predictive algorithms to maximize the ability of its products, write Tom Agan and Fred Geyer.

Emil Eifrem examines how life science researchers can uncover new insights using the in-built power of graph technology.

Christopher Rudolf and Adam Sherlock explain how artificial intelligence can transform that challenging scenario through the application of reliable and efficient life sciences web and social listening as an integral part of safety monitoring.

Clinical trial data from completed trials are now beginning to be shared through a variety of channels. While skeptics remain, evidence is growing that this data can lead to practice-changing behavior in patient care.

The absence of pharma brands on social media creates a significant void of reputable healthcare information to aid patients, writes Dawn Lacallade.

Charles Benaiah, CEO of New York's watzan, tells Pharm Exec that the key to effective social media marketing is personalization.

If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change.

While technology is already impacting the pharma industry, automation and the Internet of things (IoT) will intensify over the next two years, and those companies that experiment and embrace it will have a “dramatic and competitive advantage.”

Pharma must develop digital identity strategies for creating seamless, safe and compliant customer journeys, writes Jamie Beckland.

If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change, writes Peter Muller.

Pilot study affirms the value of a standards-based solution for prescription drug traceability-and the need to start now to meet compliance deadlines for the Drug Supply Chain Security Act.

While it is foundational to commercial operations, most European life sciences companies are not getting what they need from their customer data, writes Guillame Roussel.

With big data one of the hot healthcare topics of the moment, we gauge pharma’s response to the hype to see if the industry is poised to take advantage of the promise of advanced analytics.